{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"2.6","value":"2.3"},{"groupId":"OG001","lowerLimit":"3.1","upperLimit":"7.7","value":"3.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Progression Free Survival (PFS): time from the date of first infusion to the date of documented progression or death","dispersionType":"Full Range","groups":[{"description":"Plitidepsin 5 mg/m2 given as a 3-hour i.v. infusion every two weeks.","id":"OG000","title":"Plitidepsin"},{"description":"Plitidepsin 5 mg/m2 given as a 3-hour i.v. infusion every two weeks plus 20 mg of oral dexamethasone every day on days 1 to 4 of each cycle, starting at the same time than the plitidepsin infusion.","id":"OG001","title":"Plitidepsin + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Per protocol - Only 21 of 32 and 8 of 19 enrolled patients were evaluable (analyzed patients)","reportingStatus":"POSTED","timeFrame":"Every 2 weeks until progression or death occurs. Median PFS and PFS rates at 3 months and 6 months were assessed.","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}